PHASE I STUDY OF A DNA-BASED VACCINE TARGETING PROSTATIC ACID PHOSPHATASE (PAP)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这将是一项剂量递增研究，旨在确定基于DNA的疫苗连续皮内接种的安全性，并确定是否可以通过编码PAP的质粒DNA疫苗免疫D0期前列腺癌患者产生PAP特异性T细胞。这将是一项剂量递增研究，剂量水平将由质粒DNA疫苗剂量设计。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This will be a dose escalation study designed to determine the safety of serial intradermal vaccinations of a DNA-based vaccine and to determine if PAP-specific T cells can be generated in patients with stage D0 prostate cancer by means of immunization with a plasmid DNA vaccine encoding PAP. This will be a dose escalation study and dose levels will be designed by plasmid DNA vaccine dose.